Meeting
2019 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.
Authors
Heather L. McArthur
Cedars-Sinai Medical Center, Los Angeles, CA
Heather L. McArthur , Michail Ignatiadis , Sebastian Guillaume , Andrew Bailey , Jorge Luis Martinez , Mariana Brandao , Otto Metzger , Catherine Lai , Debora Fumagalli , Fergus Daly , Aicha Bouhlel , Valeria Karusinova , Christie Freeman , Giuseppe Viale , Vanessa Honvault , Carter Dufrane , Anh Nguyen Duc , Martine J. Piccart , Eric S. Winer , Richard D. Gelber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03498716
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS598)
DOI
10.1200/JCO.2019.37.15_suppl.TPS598
Abstract #
TPS598
Poster Bd #
89a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji
Poster
2017 ASCO Annual Meeting
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
First Author: Charles E. Geyer Jr.
Poster
2014 ASCO Annual Meeting
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
First Author: Gunter Von Minckwitz
Poster
2021 ASCO Annual Meeting
PD-L1 expression and TOP3A mutation as prognostic factors for adjuvant chemotherapy in triple negative breast cancer.
First Author: Xue Wang